JP2025510311A - Ｔｙｋ２阻害剤およびその使用 - Google Patents

Ｔｙｋ２阻害剤およびその使用 Download PDF

Info

Publication number
JP2025510311A
JP2025510311A JP2024557475A JP2024557475A JP2025510311A JP 2025510311 A JP2025510311 A JP 2025510311A JP 2024557475 A JP2024557475 A JP 2024557475A JP 2024557475 A JP2024557475 A JP 2024557475A JP 2025510311 A JP2025510311 A JP 2025510311A
Authority
JP
Japan
Prior art keywords
patient
disease
compound
weeks
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510311A5 (enExample
Inventor
ナン，フィリップ
Original Assignee
アルミス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルミス インコーポレイテッド filed Critical アルミス インコーポレイテッド
Publication of JP2025510311A publication Critical patent/JP2025510311A/ja
Publication of JP2025510311A5 publication Critical patent/JP2025510311A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024557475A 2022-03-29 2023-03-29 Ｔｙｋ２阻害剤およびその使用 Pending JP2025510311A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263324754P 2022-03-29 2022-03-29
US63/324,754 2022-03-29
US202263344126P 2022-05-20 2022-05-20
US63/344,126 2022-05-20
US202263408572P 2022-09-21 2022-09-21
US63/408,572 2022-09-21
US202263429720P 2022-12-02 2022-12-02
US63/429,720 2022-12-02
PCT/US2023/016677 WO2023192351A1 (en) 2022-03-29 2023-03-29 Tyk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025510311A true JP2025510311A (ja) 2025-04-14
JP2025510311A5 JP2025510311A5 (enExample) 2026-04-06

Family

ID=86142785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557475A Pending JP2025510311A (ja) 2022-03-29 2023-03-29 Ｔｙｋ２阻害剤およびその使用

Country Status (11)

Country Link
US (1) US20250205211A1 (enExample)
EP (1) EP4499092A1 (enExample)
JP (1) JP2025510311A (enExample)
KR (1) KR20240166011A (enExample)
CN (1) CN119546299A (enExample)
AU (1) AU2023245329A1 (enExample)
CA (1) CA3246725A1 (enExample)
IL (1) IL315866A (enExample)
MX (1) MX2024011860A (enExample)
TW (1) TW202342000A (enExample)
WO (1) WO2023192351A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121909018A (zh) * 2023-09-20 2026-04-21 阿鲁米斯公司 Tyk2抑制剂的立即释放制剂
WO2026136251A1 (en) * 2024-12-16 2026-06-25 Alumis Inc. Tyk2 inhibitor for treating neuroinflammatory or neurodegenerative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
US20230295119A1 (en) * 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines

Also Published As

Publication number Publication date
MX2024011860A (es) 2024-11-08
KR20240166011A (ko) 2024-11-25
TW202342000A (zh) 2023-11-01
CA3246725A1 (en) 2023-10-05
US20250205211A1 (en) 2025-06-26
IL315866A (en) 2024-11-01
WO2023192351A1 (en) 2023-10-05
EP4499092A1 (en) 2025-02-05
AU2023245329A1 (en) 2024-10-10
CN119546299A (zh) 2025-02-28

Similar Documents

Publication Publication Date Title
EP1741446B1 (en) Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
US11896595B2 (en) JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US20240366585A1 (en) Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
US20120053189A1 (en) Btk inhibitors for the treatment of immune mediated conditions
US20250205211A1 (en) Tyk2 inhibitors and uses thereof
JP2023542878A (ja) 多発性硬化症を治療するためのｌｏｕ０６４
US20060083714A1 (en) Combination of a pde iv inhibitor and a tnf-alpha antagonist
CN110545812A (zh) 包含pde9抑制剂的药物组合物
JP2025510813A (ja) Ｔｙｋ２阻害剤及びその使用
WO2024223740A1 (en) Treating psoriasis using a small molecule inhibitor of tumor necrosis factor alpha
WO2023105035A1 (en) Crystalline form of (r)-2-(tert-butylamino)-1-(5-fluoropyridin-3-yl)-ethan-1-ol hemi-tartrate salt for the treatment of hyperglycemia and diabetes 2
WO2025027388A1 (en) Obefazimod for treatment of ulcerative colitis
US20230158033A1 (en) Method of Treating Pemphigus by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile
US20250170158A1 (en) Methods of treating medical conditions using censavudine or a related compound
JP2026510948A (ja) 慢性閉塞性肺疾患患者におけるエンテロウイルスの治療方法
AU2023393624A1 (en) Anti-ilt7 binding agents for the treatment and prevention of myositis
CN121057588A (zh) 用于在儿科患者中治疗迟发性庞贝病的方法
CN121001736A (zh) 用于在儿科患者中治疗婴儿型庞贝病的fexa方法
TW202304446A (zh) 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
CN110804642A (zh) Gpr174免疫学功能及其用途
HK40113661A (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
CN121909018A (zh) Tyk2抑制剂的立即释放制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260327